Event

This month in kidney cancer research thumbnail image

This month in kidney cancer research

Event, Research

Welcome to our series where we take a look at what’s happening in kidney cancer each month! From treatments and clinical trials to genetic testing and government regulations, the KCA’s Medical Director, Sallie McAdoo, MS, CGC, will show you what’s new and why it matters. This month’s update was pushed back a little so that I could include my insights…

National Black Family Cancer Awareness Week is here thumbnail image

National Black Family Cancer Awareness Week is here

June 17-23, 2021 marks the first National Black Family Cancer Awareness Week - #BlackFamCan - an initiative by the FDA's Oncology Center of Excellence, Project Community, to increase cancer awareness in one of the most vulnerable segments of the US population. The KCA is supporting this initiative because increased awareness about the risks and symptoms of kidney cancer has the…

Catch our Facebook Live on the

Catch our Facebook Live on the "Secret Language" of Clinical Trials

Participating in a clinical trial often requires learning a whole new set of terminology. During the KCA's latest Facebook Live event, Medical Director Sallie McAdoo, MS, CGC, moderated a conversation with survivor and patient advocate Peggy Zuckerman and Meghara Walsh, RN, BSN, of the Dana-Farber Cancer Institute, about the complex language that often accompanies clinical trial enrollment. To help remember…

What is the 76K Challenge? thumbnail image

What is the 76K Challenge?

Over 76,000 people will be diagnosed with kidney cancer this year, according to the American Cancer Society. Together, we can support kidney cancer research that changes lives. The KCA is raising $76,000 in June for those who will receive a diagnosis this year. In honor of World Kidney Cancer Day on June 17, we're matching donations dollar-for-dollar. Meaning, you can…

Highlights from EIKCS 2021

Last week, the Kidney Cancer Association hosted the 2021 European International Kidney Cancer Symposium virtually to gather top researchers and discuss trends, changes, and new developments in the field. Dr. David McDermott Of note, “cure” was a central part of the keynote address by Dr. David McDermott of Beth Israel Deaconess Medical Center in Boston. McDermott posed this question to…

Watch our Facebook Live on clinical trial basics thumbnail image

Watch our Facebook Live on clinical trial basics

Last week, the KCA hosted its very first live streaming event! The KCA's Medical Director Sallie McAdoo, MS, CGC, moderated a Facebook Live conversation on the basics of clinical trials. To help lend expertise, two members of the KCA's Patient and Caregiver Advisory Council - John Ferrell and Peggy Zuckerman - spoke about their personal experiences participating in clinical trials…

Wrapping up our 30th anniversary thumbnail image

Wrapping up our 30th anniversary

Event, Research

As the 30th anniversary of the Kidney Cancer Association comes to a close, we are taking stock of some of the milestones and initiatives this community has been a part of. Since it was founded in 1990, the KCA and the kidney cancer community have seen kidney cancer evolve from a disease with few treatment options and a limited future…

Highlights from IKCS 2020 and the Virtual Patient Symposium

Below, we've linked highlights from research presented at IKCS 2020, the KCA’s fall symposium, which took place on November 6-7, as well as selections from the KCA’s first annual Virtual Patient Symposium on November 7. IKCS 2020 Cabozantanib is the center of emerging treatment approaches in advanced RCC - OncLive Frontline lenvatinib/everolimus combo is active in non-clear cell RCC -…

IKCS 2020 to feature three special lectures

IKCS 2020 will feature three special lectures: a keynote address by 2019 Nobel Laureate Dr. William G. Kaelin and two memorial lectures from the recipients of the KCA’s Andrew C. Novick Award and the Pieter de Mulder Memorial Award. IKCS 2020, to be held November 6-7, will be the first virtual symposium in the KCA’s 30-year history. It is also…

Highlights from ESMO’s 2020 Virtual Congress thumbnail image

Highlights from ESMO’s 2020 Virtual Congress

Here are some of the studies presented at the European Society for Medical Oncology’s recent virtual congress that grabbed our attention. Nivolumab plus cabozantinib could be a new first-line treatment option People with advanced or metastatic kidney cancer who were treated with the novel combination of the PD-1 checkpoint inhibitor nivolumab (Opdivo) plus the cabozantinib (Cabometyx) lived longer and without…

« Previous 1 2 3 4 Next »